Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile is a synthetic small molecule belonging to the indole class of organic compounds, characterized by an indole moiety with a substituted hydroxypropyl and tert-butylamino side chain. It has a molecular formula of C16H21N3O2 and a molecular weight of approximately 287.36 g/mol[1][3]. The compound is listed as experimental and does not have any approved medical indications or known clinical use as of now[3]. Its mechanism of action, biological targets, pharmacological activity, and therapeutic potential are not described in publicly available drug databases. There are no records indicating it has reached clinical trials or been developed for any disease area[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile.